Adjusted outcomes at 6 months among patients with ulcerative colitis initiating treatment with vedolizumab versus tofacitinib following anti-TNF therapy.
| . | Reference group . | Point estimate . | LCL mean . | UCL mean . | P . |
|---|---|---|---|---|---|
| Primary outcomes | |||||
| Pain Interferencea | Vedolizumab | −4.21 | −8.30 | −0.11 | .044 |
| Fatiguea | Vedolizumab | −1.25 | −5.16 | 2.66 | .531 |
| Secondary outcomes | |||||
| Social Role Satisfactiona | Vedolizumab | 3.98 | −0.18 | 8.15 | .061 |
| PRO2a | Vedolizumab | −0.32 | −0.99 | 0.35 | .349 |
| . | Reference group . | Point estimate . | LCL mean . | UCL mean . | P . |
|---|---|---|---|---|---|
| Primary outcomes | |||||
| Pain Interferencea | Vedolizumab | −4.21 | −8.30 | −0.11 | .044 |
| Fatiguea | Vedolizumab | −1.25 | −5.16 | 2.66 | .531 |
| Secondary outcomes | |||||
| Social Role Satisfactiona | Vedolizumab | 3.98 | −0.18 | 8.15 | .061 |
| PRO2a | Vedolizumab | −0.32 | −0.99 | 0.35 | .349 |
| . | . | Odds ratio . | 95% Wald confidence limits . | P . | |
|---|---|---|---|---|---|
| Colectomyb | Vedolizumab | 0.69 | 0.191 | 2.526 | .580 |
| Index medication persistenceb | Vedolizumab | 1.22 | 0.556 | 2.657 | .625 |
| . | . | Odds ratio . | 95% Wald confidence limits . | P . | |
|---|---|---|---|---|---|
| Colectomyb | Vedolizumab | 0.69 | 0.191 | 2.526 | .580 |
| Index medication persistenceb | Vedolizumab | 1.22 | 0.556 | 2.657 | .625 |
aEstimates for Patient Reported Measurement Information System (PROMIS) measures of Fatigue, Pain Interference, and Social Satisfaction and the PRO2 represent adjusted mean differences comparing treatment with vedolizumab versus tofacitinib.
bEstimates for persistence and colectomy represent adjusted odds ratios for treatment for vedolizumab versus tofacitinib.
Adjusted outcomes at 6 months among patients with ulcerative colitis initiating treatment with vedolizumab versus tofacitinib following anti-TNF therapy.
| . | Reference group . | Point estimate . | LCL mean . | UCL mean . | P . |
|---|---|---|---|---|---|
| Primary outcomes | |||||
| Pain Interferencea | Vedolizumab | −4.21 | −8.30 | −0.11 | .044 |
| Fatiguea | Vedolizumab | −1.25 | −5.16 | 2.66 | .531 |
| Secondary outcomes | |||||
| Social Role Satisfactiona | Vedolizumab | 3.98 | −0.18 | 8.15 | .061 |
| PRO2a | Vedolizumab | −0.32 | −0.99 | 0.35 | .349 |
| . | Reference group . | Point estimate . | LCL mean . | UCL mean . | P . |
|---|---|---|---|---|---|
| Primary outcomes | |||||
| Pain Interferencea | Vedolizumab | −4.21 | −8.30 | −0.11 | .044 |
| Fatiguea | Vedolizumab | −1.25 | −5.16 | 2.66 | .531 |
| Secondary outcomes | |||||
| Social Role Satisfactiona | Vedolizumab | 3.98 | −0.18 | 8.15 | .061 |
| PRO2a | Vedolizumab | −0.32 | −0.99 | 0.35 | .349 |
| . | . | Odds ratio . | 95% Wald confidence limits . | P . | |
|---|---|---|---|---|---|
| Colectomyb | Vedolizumab | 0.69 | 0.191 | 2.526 | .580 |
| Index medication persistenceb | Vedolizumab | 1.22 | 0.556 | 2.657 | .625 |
| . | . | Odds ratio . | 95% Wald confidence limits . | P . | |
|---|---|---|---|---|---|
| Colectomyb | Vedolizumab | 0.69 | 0.191 | 2.526 | .580 |
| Index medication persistenceb | Vedolizumab | 1.22 | 0.556 | 2.657 | .625 |
aEstimates for Patient Reported Measurement Information System (PROMIS) measures of Fatigue, Pain Interference, and Social Satisfaction and the PRO2 represent adjusted mean differences comparing treatment with vedolizumab versus tofacitinib.
bEstimates for persistence and colectomy represent adjusted odds ratios for treatment for vedolizumab versus tofacitinib.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
